

# Bevacizumab and endothelium dependent vasodilation

Published: 28-12-2009

Last updated: 04-05-2024

To determine the effect of bevacizumab on the vasodilator response of acetylcholine in humans by using plethysmography. To determine the effect of bevacizumab on the vasodilator response of nitroprusside in humans by using plethysmography

|                              |                                 |
|------------------------------|---------------------------------|
| <b>Ethical review</b>        | Approved WMO                    |
| <b>Status</b>                | Recruitment stopped             |
| <b>Health condition type</b> | Vascular hypertensive disorders |
| <b>Study type</b>            | Interventional                  |

## Summary

### ID

NL-OMON32503

### Source

ToetsingOnline

### Brief title

BVZach

### Condition

- Vascular hypertensive disorders

### Synonym

high blood pressure, Hypertension

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Universitair Medisch Centrum Sint Radboud

**Source(s) of monetary or material Support:** KWF/ NFCVE

## Intervention

**Keyword:** Bevacizumab, Fore arm vascular tone, Hypertensie, VEGF-inhibitor

## Outcome measures

### Primary outcome

The forearm vasomotor response to increasing doses of intra-arterially administered acetylcholine (two doses each) before and during administration of bevacizumab, expressed as percentage change in forearm blood flow ratio (flow infused arm/flow control arm) from baseline.

### Secondary outcome

na

## Study description

### Background summary

The introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. One of the most reported side effects of angiogenesis inhibitors is hypertension. In patients treated with bevacizumab, a monoclonal antibody against vascular endothelial growth factor, hypertension had an overall incidence up to 32%. The increase in blood pressure occurs early in treatment. The etiology of hypertension caused by treatment with angiogenesis inhibitors is unclear. Understanding the pathogenesis of this side effect is essential for optimal treatment with this class of drugs.

One of the main targets of angiogenesis-inhibitors is vascular endothelial growth factor and its receptors. Animal and human studies show that VEGF induces vasodilation and hypotension by stimulation of NO production. Furthermore animal studies suggest that endogenous VEGF may play a role in maintaining normal vascular tone in blood vessels.

Theoretically inhibition of VEGF or VEGFr in humans would decrease NO production causing vasoconstriction and thereby induce hypertension.

As shown in previous studies(11;12) endothelial function ( NO-dependent respons) is diminished by treatment with a VEGF-inhibitor. However these studies do not allow a conclusion on the direct causal relationship between VEGF inhibition and alteration in endothelial function. In this study we will infuse bevacizumab in the brachial artery and measure its effect on the

vasodilator response to acetylcholine. This allows us to separate local direct effects of bevacizumab on the endothelium from systemic actions such as blood pressure that could indirectly interfere with endothelial function. If appropriate, we will also study the interaction between bevacizumab and nitroprusside to explore specificity of the interaction between Ach and bevacizumab

## **Study objective**

To determine the effect of bevacizumab on the vasodilator response of acetylcholine in humans by using plethysmography.

To determine the effect of bevacizumab on the vasodilator response of nitroprusside in humans by using plethysmography

## **Study design**

This is a single center, interventional controlled trial.

The brachial artery will be cannulated (20 gauge catheter) for infusion of bevacizumab, acetylcholine or nitroprusside and measurement of arterial blood pressure. Forearm blood flow will be assessed by venous occlusion strain gauge plethysmography.

If the vasodilation caused by infusion of acetylcholine is diminished by simultaneous infusion of bevacizumab twelve new healthy subjects will be recruited in the same way for the second part of this study. In the second group the forearm blood flow response to nitroprusside alone and during simultaneous infusion of bevacizumab will be assessed using strain gauge plethysmography to study if the effect of the diminished vasodilator response to acetylcholine during bevacizumab infusion is endothelium dependent. If there is no effect of bevacizumab on the vasomotor response to acetylcholine the second part of the study will not be conducted and the total number of subjects will stay twelve.

## **Intervention**

The brachial artery will be cannulated (20 gauge catheter) for infusion of bevacizumab 144 microgram/dl forearm volume ( 15 minutes).

## **Study burden and risks**

Intra-arterial infusion of bevacizumab allows the use of very low cumulative doses that reach local concentrations in the infused forearm that are sufficient to induce a local effect with very low systemic concentrations. In a study to evaluate the short-term safety of systemic bevacizumab (5mg/kg) in patients with age-related macular degeneration no adverse events were reported except hypertension. In our previous experiment infusion of the same concentration of bevacizumab during the same amount of time no side effects

were reported.

During plethysmography, wrist cuffs are inflated to exclude the hand (mainly skin) circulation from the experimental preparation. This will cause rapidly reversible numbness and discomfort in both hands due to inflation of the wrist-cuffs. The subjects will not benefit directly from participating in this study.

## Contacts

### **Public**

Universitair Medisch Centrum Sint Radboud

Postbus 9101  
6500HB Nijmegen  
NL

### **Scientific**

Universitair Medisch Centrum Sint Radboud

Postbus 9101  
6500HB Nijmegen  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### **Age**

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

1. Age 18-50 years old
2. Male
3. Results of serum glucose, lipids and creatinine should be within the laboratory's reference ranges.

4. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.

## Exclusion criteria

1. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
2. History of or current abuse of drugs, alcohol or solvents.
3. History of malignant disease.
4. First degree relatives with a history of cancer before the age of 50
5. First degree relatives with a history of premature cardiovascular disease before the age of 50
6. Current use of medication.
7. Hypertension ( systole >140mmHG, diastole >90mmHg)
8. Diabetes mellitus
9. Smoking
10. Any clinically relevant abnormality on ECG.
11. A history of thrombosis or first degree family members with a history of recurrent thrombosis
12. Inability to understand the nature and extent of the trial and the procedures required.
14. Previous participation in a study with bevacizumab.

## Study design

### Design

|                     |                             |
|---------------------|-----------------------------|
| Study type:         | Interventional              |
| Intervention model: | Other                       |
| Allocation:         | Randomized controlled trial |
| Masking:            | Open (masking not used)     |
| Control:            | Placebo                     |
| Primary purpose:    | Treatment                   |

### Recruitment

|                           |                     |
|---------------------------|---------------------|
| NL                        |                     |
| Recruitment status:       | Recruitment stopped |
| Start date (anticipated): | 01-06-2010          |
| Enrollment:               | 24                  |
| Type:                     | Actual              |

## Medical products/devices used

|               |                               |
|---------------|-------------------------------|
| Product type: | Medicine                      |
| Brand name:   | Avastin                       |
| Generic name: | Bevacizumab                   |
| Registration: | Yes - NL outside intended use |

## Ethics review

|                    |                                      |
|--------------------|--------------------------------------|
| Approved WMO       |                                      |
| Date:              | 28-12-2009                           |
| Application type:  | First submission                     |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |
| Approved WMO       |                                      |
| Date:              | 22-04-2010                           |
| Application type:  | First submission                     |
| Review commission: | CMO regio Arnhem-Nijmegen (Nijmegen) |

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

| Register | ID                     |
|----------|------------------------|
| EudraCT  | EUCTR2009-017970-18-NL |
| CCMO     | NL31012.091.09         |